1. Home
  2. BDTX vs AGEN Comparison

BDTX vs AGEN Comparison

Compare BDTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDTX
  • AGEN
  • Stock Information
  • Founded
  • BDTX 2014
  • AGEN 1994
  • Country
  • BDTX United States
  • AGEN United States
  • Employees
  • BDTX N/A
  • AGEN N/A
  • Industry
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BDTX Health Care
  • AGEN Health Care
  • Exchange
  • BDTX Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • BDTX 292.0M
  • AGEN 286.0M
  • IPO Year
  • BDTX 2020
  • AGEN 2000
  • Fundamental
  • Price
  • BDTX $5.78
  • AGEN $7.30
  • Analyst Decision
  • BDTX Strong Buy
  • AGEN Buy
  • Analyst Count
  • BDTX 3
  • AGEN 2
  • Target Price
  • BDTX $13.00
  • AGEN $54.50
  • AVG Volume (30 Days)
  • BDTX 855.1K
  • AGEN 938.2K
  • Earning Date
  • BDTX 08-09-2024
  • AGEN 08-06-2024
  • Dividend Yield
  • BDTX N/A
  • AGEN N/A
  • EPS Growth
  • BDTX N/A
  • AGEN N/A
  • EPS
  • BDTX N/A
  • AGEN N/A
  • Revenue
  • BDTX N/A
  • AGEN $161,416,000.00
  • Revenue This Year
  • BDTX N/A
  • AGEN $43.78
  • Revenue Next Year
  • BDTX N/A
  • AGEN N/A
  • P/E Ratio
  • BDTX N/A
  • AGEN N/A
  • Revenue Growth
  • BDTX N/A
  • AGEN 69.94
  • 52 Week Low
  • BDTX $1.62
  • AGEN $4.78
  • 52 Week High
  • BDTX $7.66
  • AGEN $34.20
  • Technical
  • Relative Strength Index (RSI)
  • BDTX 59.02
  • AGEN 28.20
  • Support Level
  • BDTX $4.28
  • AGEN $14.77
  • Resistance Level
  • BDTX $6.28
  • AGEN $18.74
  • Average True Range (ATR)
  • BDTX 0.39
  • AGEN 1.55
  • MACD
  • BDTX 0.16
  • AGEN -0.45
  • Stochastic Oscillator
  • BDTX 76.53
  • AGEN 8.62

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: